Novartis AG
MULTISPECIFIC MOLECULES TARGETING CLL-1
Last updated:
Abstract:
The present invention is directed to multispecific/multivalent molecules comprising an anti-CLL-1 binding domain.
Status:
Application
Type:
Utility
Filling date:
20 Jan 2017
Issue date:
1 Jul 2021